Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.180
-0.060 (-4.84%)
At close: Sep 4, 2026, 4:00 PM EDT
1.200
+0.020 (1.69%)
After-hours: Sep 4, 2026, 7:57 PM EDT
Marker Therapeutics Revenue
Marker Therapeutics had revenue of $681.58K in the quarter ending June 30, 2026, a decrease of -20.86%. This brings the company's revenue in the last twelve months to $3.77M, down -30.04% year-over-year. In the year 2025, Marker Therapeutics had annual revenue of $3.55M, down -46.19%.
Revenue (ttm)
$3.77M
Revenue Growth
-30.04%
P/S Ratio
5.55
Revenue / Employee
$709,334
Employees
5
Market Cap
19.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.55M | -3.04M | -46.19% |
| Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
| Dec 31, 2023 | 3.31M | -5.70M | -63.26% |
| Dec 31, 2022 | 9.01M | 7.77M | 625.90% |
| Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
| Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
| Dec 31, 2019 | 213.19K | 7.20K | 3.50% |
| Dec 31, 2018 | 205.99K | 22.93K | 12.53% |
| Dec 31, 2017 | 183.06K | -48.14K | -20.82% |
| Dec 31, 2016 | 231.20K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Cerenome | 4.20M |
| Cyclerion Therapeutics | 1.90M |
| Longeveron | 1.19M |
| Cocrystal Pharma | 330.00K |
| Lexaria Bioscience | 194.00K |
| Neuphoria Therapeutics | -13.27K |
MRKR News
- 22 days ago - Marker Therapeutics Quarterly report: Q2 2026 - Filings
- 3 months ago - Marker Therapeutics Quarterly report: Q1 2026 - Filings
- 5 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings
- 5 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings
- 5 months ago - Marker Therapeutics reports FY25 EPS (79c), two estimates (94c) - TheFly
- 5 months ago - Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewsWire
- 5 months ago - Marker Therapeutics Earnings release: Q4 2025 - Filings
- 5 months ago - Marker Therapeutics Annual report: Q4 2025 - Filings